Melacure, Eli Lilly deal

Melacure will begin a Phase II trial with LLY to develop Melacure’s glucagon-like peptide-1 (GLP-1) to treat irritable bowel syndrome (IBS) and functional dyspepsia. LLY will manufacture the clinical...